55 completed, 7 terminated, 6 unknown, 3 recruiting. 73 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 73 | Completed 55, Terminated 7, Unknown 6, Recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Unknown 1 |
Follow Candidiasis: new trials by email Literature Review of Candidiasis trials Research Report on Candidiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis Boric acid, Placebo - Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | pH-D Feminine Health LLC | 333 | 2025-08-08 | 2026-10-23 |
| A Randomized Study of a Short Duration Therapy for Candidemia Standard of Care (SOC), Shortened duration of antifungal therapy - CANDIDEMIA | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 362 | 2025-07-01 | 2025-03-05 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Amphotericin B cholesteryl Sulfate Complex for Injection - Invasive Candidiasis, Invasive Aspergillosis | Phase 3 | Completed | CSPC Ouyi Pharmaceutical Co., Ltd. | 31 | 2023-03-30 | 2025-04-09 |
| Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories - Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | Avva Rus, JSC | 218 | 2022-12-29 | 2024-05-13 |
| The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Fluconazole, L-Mesitran - Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina | Phase 3 | Recruiting | Maastricht University Medical Center | 252 | 2022-08-22 | 2023-05-17 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Ibrexafungerp - Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 150 | 2022-05-01 | 2024-07-10 |
| A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis SHR8008, Fluconazole - Recurrent Vulvovaginal Candidiasis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 196 | 2021-09-14 | 2021-10-12 |
| Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection. Fluconazole, Saline - Invasive Candidiases | Phase 3 | Completed | Services Institute of Medical Sciences, Pakistan | 110 | 2021-05-01 | 2023-05-08 |
| Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule EVEGYN A, EVEGYN B, Gynomax® XL Vaginal Ovule - Trichomonal Vaginitis, Bacterial Vaginosis | Phase 3 | Completed | Ege University | 577 | 2020-07-20 | 2023-09-28 |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 440 | 2019-10-21 | 2023-06-18 |
| A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis | Phase 2 / Phase 3 | Unknown | ProFem GmbH | 432 | 2019-10-01 | 2022-09-22 |
| Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Ibrexafungerp, Placebo - Candida Vulvovaginitis | Phase 3 | Completed | Scynexis, Inc. | 455 | 2019-06-07 | 2021-09-08 |
| Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 219 | 2019-03-13 | 2022-02-04 |
| Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) Ibrexafungerp, Placebo - Candida Vulvovaginitis | Phase 3 | Completed | Scynexis, Inc. | 376 | 2019-01-04 | 2021-09-08 |
| Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis caspofungin antifungal therapy, placebo - ICU Yeast Intra-abdominal Infection | Phase 3 | Unknown | Centre Hospitalier Universitaire, Amiens | 448 | 2019-01-01 | 2024-07-10 |
Showing 20 of 73. Sign in to see all of them.
Candidiasis, Vulvovaginal (25) · Candidemia (20) · Candidiasis, Invasive (17) · Mycoses (17) · Torulopsis (9) · Candidiasis, Oral (7) · Fungemia (7) · Aspergillosis (6) · Invasive Fungal Infections (5) · Vaginosis, Bacterial (4) · Cryptococcosis (3) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Blastomycosis (2)
Bacterial Infections and Mycoses (73) · Infections (72) · Mycoses (56) · Genital Diseases (30) · Urogenital Diseases (30) · Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Genital Diseases, Female (27) · Vaginal Diseases (26) · Vulvar Diseases (25) · Vulvitis (25) · Invasive Fungal Infections (24) · Pathological Conditions, Signs and Symptoms (24) · Vaginitis (24)
Fluconazole (25) · Micafungin (10) · Caspofungin (9) · Anidulafungin (7) · ibrexafungerp (7) · Voriconazole (5) · Clotrimazole (4) · Injections (4) · Amphotericin B (3) · VT-1161 (3) · posaconazole (3) · Clindamycin (2) · Ketoconazole (2) · Lactulose (2) · Rezafungin (2)
Pfizer (11) · Scynexis, Inc. (7) · Astellas Pharma Inc (6) · National Cancer Institute (NCI) (6) · Merck Sharp & Dohme LLC (4) · Mycovia Pharmaceuticals Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ProFem GmbH (2) · AVVA Pharmaceuticals Ltd. (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Astellas Pharma Global Development, Inc. (1) · Avva Rus, JSC (1) · Basilea Pharmaceutica (1) · Bayer (1)
United States (32) · France (12) · Belgium (9) · Brazil (9) · Canada (9) · Germany (9) · Italy (9) · Spain (9) · China (8) · Russia (8) · Netherlands (7) · South Africa (7) · Austria (6) · Bulgaria (6) · Greece (6)
David Angulo, MD (3) · Alexandra Hill, MD (1) · Andrea E Rodriguez, MD, MsC (1) · Ariel I Ruiz, MD, MsC (1) · Baodong Ye (1) · Bozzettee S (1) · Corine Delsing, MD (1) · Daniel K Benjamin, MD MPH PhD (1) · ELizabeth M Molyneux, FRCPCH FFAEM (1) · Edith Muller, M.D (1)
PMID 28459966, PMID 28597967, PMID 33891293, PMID 31280481, PMID 36396498, PMID 21147825, PMID 23959319, PMID 33438477, PMID 36255448, PMID 38319878, PMID 16161031, PMID 17128343, PMID 17568028, PMID 18696746, PMID 18813103, PMID 19485785, PMID 19804626, PMID 19915602, PMID 21961941, PMID 22026929, PMID 23676114, PMID 24261608, PMID 24669841, PMID 24794367, PMID 25887336, PMID 25902926, PMID 26916845, PMID 27636722, PMID 27706483, PMID 29596222, PMID 29744900, PMID 30289478, PMID 30418357, PMID 32032174, PMID 36442484, PMID 37640455, PMID 37773627, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 39979898, PMID 40970688, PMID 41194465, PMID 41845293, PMID 41940006
2008 (2), 2009 (2), 2017 (2), R01HD057956 (1)